Isocarboxazid: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
 
Line 32: Line 32:
[[Category:Antidepressants]]
[[Category:Antidepressants]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Monoamine oxidase inhibitors]]
<gallery>
File:Isocarboxazid structure.svg|Isocarboxazid
</gallery>

Latest revision as of 01:38, 20 February 2025

Overview of the monoamine oxidase inhibitor Isocarboxazid


Isocarboxazid
File:Isocarboxazid structure.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Isocarboxazid is a monoamine oxidase inhibitor (MAOI) used as an antidepressant in the treatment of major depressive disorder. It is one of the older classes of antidepressants and is known for its effectiveness in patients who do not respond to other treatments.

Pharmacology[edit]

Isocarboxazid works by inhibiting the activity of the enzyme monoamine oxidase, which is responsible for breaking down neurotransmitters such as serotonin, norepinephrine, and dopamine in the brain. By inhibiting this enzyme, isocarboxazid increases the levels of these neurotransmitters, which can help improve mood and alleviate symptoms of depression.

Medical uses[edit]

Isocarboxazid is primarily used to treat major depressive disorder, especially in cases where other treatments have failed. It may also be used in the treatment of anxiety disorders and panic disorder.

Side effects[edit]

Common side effects of isocarboxazid include dizziness, dry mouth, constipation, and insomnia. Due to its mechanism of action, it can also cause hypertensive crisis if taken with certain foods or other medications that increase tyramine levels.

Interactions[edit]

Isocarboxazid can interact with a variety of substances, including other antidepressants, sympathomimetic drugs, and foods high in tyramine. Patients are advised to follow a strict diet and avoid certain medications to prevent adverse reactions.

History[edit]

Isocarboxazid was first introduced in the 1950s and was one of the first MAOIs to be used clinically. Despite the development of newer antidepressants, it remains an option for treatment-resistant depression.

Related pages[edit]